( MENAFN - PR Newswire) Supporting more than 500,000 U.S. healthcare professionals, Eko combines FDA-cleared algorithms with digital medical devices to enhance the early detection of cardiac and pulmonary diseases during physical exams.
SAN FRANCISCO, June 5, 2024 /PRNewswire/ -- Eko health , a pioneer in applying artificial intelligence for early detection of heart and lung diseases, today announced it has raised $41 million in Series D financing. With participation by ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, the funding round will be used to expand U.S.
and global access to the company's early disease detection platform. The funding builds on recent commercial and clinical milestones, including U.S.
FDA clearances for its structural heart murmur and low ejection fraction (Low EF) detection algorithms. Eko's murmur detection algorithm was clinically validated in a Massachusetts General Hospital study and found to double identification rates of structural heart murmurs versus conventional practice in primary care. The low EF detection algorithm, developed with Mayo Clinic, was shown in an Imperial College London study to significantly enhance the identification of heart failure with reduced ejection fraction in GP clinics.
By enhancing detection capabilities, Eko's platform significantly reduces diagnostic bottlenecks, leading to earlier interventions and improved patient outcomes. "Eko harnesses AI to unlock universal access to expert-level cardi.
